Merck’s Mark DiNubile Joins BioAegis as Chief Medical Officer

Mark DiNubile has joined BioAegis Therapeutics as chief medical officer. DiNubile previously spent 16 years at Merck (NYSE: [[ticker:MRK]]), where his work focused on infectious diseases and vaccines. North Brunswick, NJ-based BioAegis is a clinical stage company developing treatments for inflammation and infection. The company’s lead drug is in Phase 2 studies as a potential treatment for community-acquired bacterial pneumonia patients admitted to the intensive care unit.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.